purpos
aim
studi
compar
serum
procalcitonin
pct
level
febril
children
kawasaki
diseas
kd
bacteri
viral
infect
assess
clinic
use
pct
level
predict
kd
method
serum
pct
level
examin
febril
pediatr
patient
admit
august
august
patient
divid
group
follow
kd
viral
infec
tion
bacteri
infect
result
mean
pct
level
kd
group
significantli
lower
bacteri
infect
group
ngml
vs
ngml
insignificantli
differ
viral
infect
group
ngml
mean
erythrocyt
sediment
rate
esr
creactiv
protein
crp
level
kd
group
significantli
higher
viral
bacteri
infect
group
p
p
esr
p
crp
respect
proport
patient
kd
group
pct
level
ngml
significantli
higher
nonrespond
initi
intraven
immunoglobulin
treatment
respond
vs
conclus
pct
level
may
help
differenti
kd
bacteri
infect
combin
diseas
marker
includ
esr
crp
pct
may
use
differenti
kd
viralbacteri
infect
procalcitonin
pct
prehormon
calcitonin
releas
respons
proinflam
matori
stimuli
particularli
bacteriaassoci
mediat
recent
pct
frequent
use
biomark
sepsi
creactiv
protein
crp
anoth
acutephas
reactant
studi
pct
level
adult
patient
variou
inflammatori
state
pct
level
found
significantli
elev
patient
bacteri
fungal
infect
normal
slightli
elev
sever
inflammatori
diseas
furthermor
studi
pct
level
pediatr
patient
pct
found
signific
biomark
diagnos
pediatr
urinari
tract
infect
neonat
sepsi
identifi
patient
without
seriou
bacteri
infect
order
prevent
antimicrobi
overus
pediatr
intens
care
unit
mani
children
present
hospit
fever
vari
etiolog
one
import
caus
fever
children
younger
year
kawasaki
diseas
kd
kd
wellknown
system
vasculit
disord
system
flammat
associ
condit
caus
elev
white
blood
cell
wbc
count
crp
level
addit
ele
vation
erythrocyt
sediment
rate
esr
diagnosi
kd
made
intraven
immunoglobulin
ivig
therapi
initi
mani
patient
kd
receiv
antibiot
oralintraven
therapi
diagnosi
kd
delay
high
esr
crp
level
commonli
thought
indi
cate
bacteri
infect
first
studi
pct
level
patient
kd
compar
pct
level
patient
diseas
report
although
clinic
impact
serum
pct
level
patient
kd
determin
relat
pct
kd
sever
comparison
pct
level
complet
incomplet
kd
also
report
aim
studi
report
experi
pct
level
febril
children
kd
bacteri
viral
infect
clinic
use
pct
level
predict
kd
evalu
serum
pct
level
febril
pediatr
patient
admit
august
august
singl
tertiari
center
fever
defin
bodi
temperatur
age
rang
enrol
patient
day
year
enrol
patient
divid
groupsth
kd
viral
infect
bacteri
infect
groupsaccord
definit
describ
complet
kd
diagnos
case
fever
persist
day
least
typic
clinic
manifest
observ
base
american
heart
associ
criteria
also
includ
patient
incomplet
kd
diagnos
fewer
four
typic
clinic
manifest
observ
base
criteria
respond
ivig
treatment
includ
patient
kd
whose
fever
subsid
within
hour
initi
treatment
wherea
nonrespon
der
includ
patient
kd
whose
fever
persist
beyond
hour
requir
addit
ivig
treatment
identifi
viral
pathogen
viru
revers
transcript
poli
meras
chain
reaction
rtpcr
ace
detect
seegen
seoul
korea
perform
nasal
throat
swab
specimen
obtain
day
admiss
rtpcr
includ
test
metapneumoviru
adenoviru
af
coronaviru
parainfluenza
viru
influenza
ab
viru
rhinoviru
spiratori
syncyti
viru
ab
bocaviru
viral
infect
diagnos
basi
posit
rtpcr
result
patient
clinic
diagnost
featur
viral
infect
hand
foot
mouth
diseas
herpangina
also
includ
bacteri
infect
confirm
posit
cultur
result
variou
sampl
patient
ie
blood
urin
cerebrospin
fluid
kd
viral
infect
confirm
rtpcr
bacteri
infect
confirm
cultur
exclud
retrospect
review
patient
characterist
clinic
cours
use
medic
record
peripher
blood
sampl
analyz
day
admi
sion
measur
marker
includ
pct
serum
pct
level
measur
use
electrochemiluminesc
immu
noassay
elecsi
brahm
pct
roch
henningsdorf
germani
detect
rang
ngml
follow
cutoff
level
pct
use
determin
whether
antibiot
treatment
would
use
pct
ngml
antibiot
strongli
discourag
ed
pct
ngml
antibiot
discourag
pct
ngml
antibiot
strongli
encourag
also
obtain
complet
blood
cell
count
esr
crp
level
serum
crp
level
measur
use
latexenhanc
immunoturbidimetri
advia
chemistri
xpt
system
siemen
erlangen
germani
studi
approv
institut
review
board
keimyung
univers
dongsan
medic
center
approv
number
statist
analys
perform
ibm
spss
statist
ver
ibm
co
armonk
ny
usa
collect
data
describ
frequenc
mean
standard
deviat
chisquar
test
use
comparison
categor
data
analysi
varianc
follow
bonferroni
post
hoc
test
multipl
comparison
use
comparison
continu
data
among
group
patient
kd
unpair
test
logist
regress
analysi
appli
compar
pct
esr
crp
level
p
valu
consid
statist
signific
total
patient
enrol
studi
includ
kd
viral
infect
bacteri
infec
tion
characterist
patient
group
shown
tabl
kd
incomplet
kd
observ
patient
respect
patient
kd
initi
treat
g
kg
ivig
mgkg
oral
aspirin
patient
classifi
respond
patient
nonrespond
patient
viral
infect
show
posit
rtpcr
result
commonli
detect
viru
respira
tori
syncyti
viru
ab
follow
rhinoviru
parainfluenza
thirteen
patient
mix
infect
kind
virus
among
patient
viral
infect
com
mon
diagnosi
acut
lower
respiratori
tract
infect
acut
bronchiol
diagnos
patient
pneumonia
patient
follow
croup
influenza
asthma
patient
diagnos
bronchi
ti
hand
foot
mouth
diseas
herpangina
influenza
fever
without
local
sign
bacteri
infect
confirm
patient
respect
basi
posit
result
blood
urin
blood
urin
cultur
patient
bacteri
infec
tion
caus
organ
staphylococcu
strep
tococcu
blood
enterococcu
escherichia
coli
klebsiella
pneumonia
urin
final
diagnos
bacteri
infect
septicemia
pneumonia
cellul
urinari
tract
infec
tion
mean
age
kd
group
significantli
higher
viral
infect
group
patient
kd
group
significantli
higher
mean
bodi
weight
viral
bacteri
infect
group
howev
mean
bodi
mass
index
significantli
differ
among
group
sex
distribut
differ
ent
among
group
durat
fever
admiss
mean
day
kd
viral
infect
bacteri
infect
group
respect
patient
kd
group
significantli
longer
fever
durat
admiss
viral
bacteri
infect
group
p
bacteri
infect
group
significantli
longer
durat
admiss
viral
infect
group
laboratori
find
patient
includ
studi
shown
tabl
mean
wbc
count
kd
bacteri
infect
group
significantli
higher
viral
infect
group
mean
neutrophil
proport
kd
group
significantli
higher
viral
infec
tion
group
p
mean
esr
kd
group
signifi
cantli
higher
viral
bacteri
infect
group
p
p
mean
crp
level
kd
infect
group
significantli
higher
viral
bacteri
group
p
p
mean
pct
level
kd
viral
bacteri
infect
group
ngml
re
pectiv
mean
pct
level
bacteri
infect
group
significantli
higher
kd
viral
infect
group
tabl
number
patient
pct
level
ngml
ngml
significantli
differ
kd
viral
infect
group
viral
infect
bacteri
infect
group
p
kd
bacteri
infect
group
kd
group
pct
level
significantli
correl
fever
durat
esr
crp
level
respect
signific
differ
pct
level
patient
complet
incomplet
kd
fig
among
nine
patient
incomplet
kd
one
pct
level
ngml
ivig
respond
nonrespond
among
patient
kd
also
signific
differ
pct
level
esr
crp
level
respect
howev
adjust
age
use
analysi
covari
ancova
signific
differ
observ
pct
crp
respond
nonrespond
kd
group
ivig
nonrespond
pct
level
ngml
pct
level
ngml
comparison
ivig
respond
pct
level
ngml
pct
level
ngml
lower
proport
nonrespond
respond
pct
level
ngml
p
higher
proport
nonrespond
respond
pct
level
ngml
fig
result
studi
demonstr
mean
pct
level
benefici
differenti
febril
children
kd
bacteri
infect
moreov
patient
kd
pct
level
ngml
tend
nonrespond
initi
ivig
treat
ment
addit
esr
crp
level
use
differ
entiat
patient
kd
viral
infec
tion
among
mani
clinic
marker
inflamm
sepsi
pct
accur
crp
differenti
bacteri
infect
noninfecti
inflamm
peak
pct
level
reach
rapidli
peak
crp
level
synthesi
mechan
pct
crp
somewhat
differ
pct
mainli
produc
liver
monocyt
secr
tion
modul
lipopolysaccharid
sepsisrel
cytokin
tumor
necrosi
factor
tnf
crp
produc
liver
mainli
respons
interleukin
il
pedia
tric
research
pct
use
studi
neutropenia
fever
young
infant
pediatr
urinari
tract
infect
pediatr
communityacquir
pneumonia
append
kd
system
vasculit
disord
lead
endotheli
cell
activ
damag
caus
increas
level
inflamma
tori
cytokin
inflamma
tori
cytokin
increas
level
acutephas
reactant
crp
pct
increas
crp
level
patient
kd
play
crucial
role
diagnosi
treatment
also
risk
factor
coronari
arteryrel
complic
howev
clinic
impact
serum
pct
level
patient
kd
determin
fever
first
symptom
appear
kd
symp
tom
usual
develop
simultan
initi
high
esr
crp
level
associ
fever
suspect
indi
cativ
bacteri
infect
henc
oral
intraven
antibiot
therapi
may
administ
usual
continu
symptom
fulfil
criteria
kd
howev
patient
kd
respond
antibiot
therapi
requir
ivig
treatment
stead
kd
difficult
inflammatori
diseas
diagnos
pct
known
biomark
sepsi
diagnos
bacteri
infect
decid
antibiot
treatment
hypothes
serum
pct
level
may
differenti
kd
infect
first
studi
pct
level
patient
kd
report
report
patient
kd
higher
mean
pct
level
patient
viral
autoimmun
diseas
healthi
children
wherea
patient
kd
bac
terial
infect
show
similar
pct
level
present
studi
also
show
similar
result
mean
pct
level
patient
kd
bacteri
infect
significantli
higher
patient
viral
infect
mean
pct
level
patient
kd
lower
patient
bacteri
infect
howev
differ
signific
specul
immun
respons
bacteri
infect
may
occur
patient
kd
although
caus
microorgan
kd
yet
confirm
definit
caus
kd
current
unknown
howev
gener
accept
kd
de
velop
result
genet
predisposit
combin
infect
undefin
trigger
autoimmun
mecha
nism
mani
bacteri
viral
agent
suggest
confirm
trigger
kd
infect
recent
bacteri
toxin
intracytoplasm
inclus
bodi
associ
viral
infect
newli
hypothes
caus
develop
kd
present
studi
pct
level
significantli
differ
patient
complet
kd
incomplet
kd
howev
nonrespond
respond
pct
level
ngml
signific
differ
pct
respond
nonrespond
kd
group
adjust
age
use
ancova
anoth
studi
investiga
ting
respond
nonrespond
initi
ivig
treatment
demonstr
pct
level
significantli
higher
non
respond
respond
result
similar
find
studi
recent
studi
enrol
patient
complet
kd
patient
incomplet
kd
show
pct
level
patient
complet
kd
signifi
cantli
higher
patient
incomplet
kd
author
describ
nonrespond
initi
ivig
frequent
complet
kd
incomplet
kd
vs
suspect
nonrespond
complet
kd
higher
pct
level
incomplet
kd
pct
level
seem
use
predict
ivig
respons
patient
kd
recent
guidelin
determin
whether
antibiot
therapi
implement
use
follow
criteria
pct
ng
ml
antibiot
strongli
discourag
pct
ngml
antibiot
discourag
pct
ngml
antibiot
strongli
enco
urag
kd
patient
present
studi
would
recommend
receiv
antibiot
pct
ng
ml
comparison
patient
viral
infect
patient
bacteri
infect
would
recommend
ed
receiv
antibiot
state
pct
level
significantli
differ
patient
kd
viral
infect
patient
viral
infect
bacteri
infect
patient
kd
bacteri
infect
although
pct
level
use
differenti
kd
bacteri
infect
esr
cpr
level
significantli
higher
patient
kd
bacteri
infect
therefor
pct
also
esr
crp
level
consid
febril
pediatr
patient
febril
patient
high
esr
crp
level
low
pct
level
addit
symptom
kd
kd
suspect
rather
bacteri
infect
limit
present
studi
small
sampl
size
especi
patient
incomplet
kd
patient
kd
ivig
nonrespond
lack
comparison
system
inflammatori
condit
autoimmun
diseas
studi
cytokin
includ
help
determin
role
pct
kd
conclus
pct
level
may
help
differenti
kd
bacteri
infect
combin
diseas
marker
includ
esr
crp
pct
may
use
differenti
kd
viral
bacteri
infect
addit
pct
level
may
somewhat
use
predict
respons
ivig
treatment
